Clinical trials: Advanced Stage
Non-small Cell Lung Cancer
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules…
- Trial name
- NCT04273815
- Testing
- TQ-A3334, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors
Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan
This study will characterize the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of AUY922 in adult patients with advanced solid malignancies in Japan.
- Trial name
- NCT01132625
- Testing
- AUY922
- Where
- 2 sites in Japan
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)
The purpose of this study is to assess the safety and tolerability of MK-0457(VX-680), an Aurora kinase inhibitor, in participants with advanced solid tumors. Bioavailability of the oral formulation will also be assessed.
- Trial name
- NCT02532868
- Testing
- MK-0457
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors
The research project is testing this potential new medication for advanced solid tumours. This research project is being done to get more information about the study drug (XNW7201).
- Trial name
- NCT03901950
- Testing
- XNW7201 tablets
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Evopoint Biosciences Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
Advanced Malignant Solid Tumors
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150…
- Trial name
- NCT07566247
- Testing
- AK150
- Where
- 3 sites in China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Akeso
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience
Advanced Solid Tumors
Study of GS-2426 in Participants With Advanced Solid Tumors
The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors.
- Trial name
- NCT07601243
- Testing
- GS-2426
- Where
- 6 sites in United States, Spain
- Volunteers
- 174 people
- Sponsor
- Gilead Sciences
Advanced or Metastatic ER+ Breast Cancer
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with…
- Trial name
- NCT02734615
- Testing
- LSZ102, LEE011, BYL719
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion study of AMG 780 in up to 62 subjects with advanced solid tumors.
- Trial name
- NCT01137552
- Testing
- AMG 780
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Amgen
Cervical Cancer, Cancer
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of…
- Conditions
- Cervical Cancer, Cancer, Head and Neck Cancer
- Trial name
- NCT02291055
- Testing
- ADXS11-001, MEDI4736
- Where
- 17 sites in United States
- Volunteers
- 75 people
- Sponsor
- Advaxis, Inc.
Breast Neoplasms
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.
- Trial name
- NCT00034125
- Testing
- LY353381, tamoxifen
- Where
- 11 sites in United States, Argentina and 3 more
- Sponsor
- Eli Lilly and Company
Gastric Cancer
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer
The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced…
- Trial name
- NCT00952497
- Testing
- Cisplatin, Capecitabine, Telatinib
- Where
- 11 sites in United States, Spain
- Volunteers
- 48 people
- Sponsor
- ACT Biotech, Inc
Neoplasms
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
- Trial name
- NCT06311578
- Testing
- JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 126 people
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
Age Related Macular Degeneration
Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
The purpose of this first in man study is to examine the safety of an experimental gene transfer agent, RetinoStat, designed to treat neovascular age-related macular degeneration.
- Trial name
- GEM (NCT01301443)
- Testing
- Subretinally injected RetinoStat
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Oxford BioMedica
Advanced Endometrial Cancer
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
This is a Phase 3, multicenter, randomized, open-label trial to evaluate whether EG-007 plus Len+Pem is superior to Len+Pem alone in patients with advanced endometrial cancer (Stage III or IV).
- Trial name
- NCT05077215
- Testing
- EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules
- Volunteers
- 450 people
- Sponsor
- Evergreen Therapeutics, Inc.
Advanced Gastric Cancer
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
Fruquintinib once daily in 4 weeks treatment cycle (three weeks on and one week off) in combination with Paclitaxel 80mg/㎡（day1, 8, 15 of 4 weeks cycle) was well tolerated and demonstrated encouraging preliminary clinical…
- Trial name
- FRUTIGA (NCT03223376)
- Testing
- fruquintinib +paclitaxel
- Where
- 7 sites in China
- Volunteers
- 703 people
- Sponsor
- Hutchison Medipharma Limited
Carcinoma, Non-Small-Cell Lung
A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
The purposes of this study are to determine: 1. If treatment with LY900003 plus gemcitabine and cisplatin can help you live longer, compared with gemcitabine and cisplatin alone. 2.
- Trial name
- NCT00034268
- Testing
- LY900003
- Where
- 105 sites in United States, Argentina and 19 more
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
This study was designed to determine the effect of jaundice on the ability of G17DT to generate antibodies before and after treatment of biliary obstruction due to advanced pancreatic cancer.
- Trial name
- PC1 (NCT02098291)
- Testing
- G17DT
- Volunteers
- 34 people
- Sponsor
- Cancer Advances Inc.